Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead…
Tempest Therapeutics, Inc. (TPST) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate -Tempest secures exclusive global rights outside China to a targeted lentiviral platform and po
- Role
- customer
- Counterparty
- Hebei Senlang Biotechnology Co., Ltd.
- Scope
- CD7-targeted lentiviral vector platform and associated in vivo CAR-T candidates
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The option exercise and early trial read‑outs provide a concrete catalyst that could move TPST shares, especially if subsequent data confirm efficacy.
Market read
First disclosure of a licensing deal and early clinical data creates a fresh catalyst for TPST, offering traders a potential entry point.
What to watch
Potential competition from LNP‑based CAR‑T platforms and the exclusion of China from the license.
Background
Tempest Therapeutics is a Nasdaq‑listed clinical‑stage biotech developing in‑vivo CAR‑T therapies. The company previously announced an option agreement with Senlang in September 2026.
Ticker impact
Tempest Therapeutics exercised its option to license Senlang's CD7‑targeted lentiviral CAR‑T platform and disclosed early Phase 1 data from 13 patients in the DELIVER‑1 study.
upward pressure as investors price in the new platform and early trial data
First‑report of a material licensing transaction combined with early efficacy signals for a dual‑targeting CAR‑T candidate.
Market effects
Strengthens the in‑vivo CAR‑T segment and may boost related gene‑therapy stocks.
Limited to US biotech investors; no broader regional effect.
Modest global relevance, primarily for biotech and immunotherapy investors.
Counterpoint
Early Phase 1 data are still limited; the platform may face regulatory or manufacturing hurdles.
Key entities
- companyTempest Therapeutics, Inc.
Nasdaq‑listed biotech developing in‑vivo CAR‑T therapies.
- companyHebei Senlang Biotechnology Co., Ltd.
Chinese cell‑therapy firm providing the licensed lentiviral platform.
